Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 9/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613097 | 0.92 | CHRNB4 (0.39) | CHRNA3CHRNB4CHRNB2CHRNA5 | |
| SCHEMBL25650732 | 0.86 | CHRNB4 (0.36) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL24005914 | 0.85 | CHRNB2 (0.47) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL25613089 | 0.84 | CNR2 (0.42) | — | |
| SCHEMBL25613092 | 0.83 | CDK2 (0.40) | — | |
| SCHEMBL25613094 | 0.83 | CDK2 (0.38) | — | |
| SCHEMBL25613114 | 0.78 | CHRNB4 (0.46) | CHRNA3CHRNB4CHRNB2CHRNA4 | |
| SCHEMBL25613103 | 0.77 | CHRNA3 (0.42) | CHRNA3CHRNB4CHRNB2CHRNA4 | |
| SCHEMBL25613088 | 0.77 | GRM4 (0.40) | — | |
| SCHEMBL25613037 | 0.76 | FEN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | CHRNA3 4861/4885CHRNB4 4865/4885CHRNB2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.